Clinical Trials
9 trialsNCT05131022 2026-04-14
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT06544265 2026-04-14
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Phase 1 Recruiting
NCT04830137 2026-03-20
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT04775745 2026-02-13
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
Phase 1 Recruiting
NCT05544019 2026-02-13
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger, Inc.
Phase 1 Recruiting
NCT05602363 2025-12-10
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences, Inc.
Phase 1 Recruiting
NCT06712810 2025-10-10
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT05780034 2025-10-02
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Accutar Biotechnology Inc
Phase 1 Recruiting
NCT06340737 2025-08-07
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
Phase 1 Recruiting